Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile

Loading news article.

Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile | WAPE

Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile

Article summary

Related companies

Comments —